Author:
Franzè S.,Cilurzo F.,Minghetti P.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Reference34 articles.
1. Minghetti P, Rocco P, Cilurzo F, Del Vecchio L, Locatelli F. The regulatory framework of biosimilars in the European Union. Drug Discov Today. 2012;17:63–70.
2. Minghetti P, Rocco P, Del Vecchio L, Locatelli F. Biosimilars and regulatory authorities. Nephron Clin Pract. 2011;117(1):C1–6.
3. European Medicines Agency. CHMP summary of positive opinion for Abasria. EMA/CHMP/340931/2014. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion__Initial_authorisation/human/002835/WC500169353.pdf . Accessed 29 Sep 2014.
4. Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res. 2008;6(2):54–67.
5. Vajo Z, Fawcett J, Duckworth WC. Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocr Rev. 2001;22(5):706–17.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献